Daratumumab
Trade name: Darzalex™
Daratumumab is the generic name for the trade name drug Darzalex. In some cases, health care professionals may use the trade name Darzalex when referring to the generic drug name daratumumab.

Drug type: Daratumumab is an anti-cancer ("antineoplastic" or "cytotoxic") drug. This medication is a monoclonal antibody directed against CD38, a molecule present on myeloma cells. (For more detail, see "How Daratumumab Works" below)

What Daratumumab Is Used For :
  • Treatment of multiple myeloma that was refractory to a combination of a proteasome inhibitor such as bortezomib (Velcade), ixazomib (Ninlaro) or carfilzomib (Kyprolis) and an immunomodulatory drug such as lenalidomide (Revlimid), thalidomide (Thalomide) or pomalidomide (Pomalyst) or that requires treatment after 3 or more lines of prior therapy that included a proteasome inhibitor and an immunomodulatory drug.

Note: If a drug has been approved for one use, physicians may elect to use this same drug for other problems if they believe it may be helpful.

How Daratumumab Is Given :
  • As an infusion into a vein (intravenous, IV) over about 8 hours with the first infusion. The time of the infusion may be shortened or extended, depending on how well you tolerate this drug after the first infusion.
  • Medications will be given one hour before the infusion to reduce the occurrence of infusion-related symptoms.
  • You may receive some medications after the infusion to prevent delayed infusion-related symptoms.
  • There is no pill form of daratumumab.
  • The usual schedule for daratumumab infusions is 8 weekly treatments, then 8 more treatments given every other week (over a 16 week period of time), then a treatment every 4 weeks.

The amount of daratumumab that you will receive depends on many factors, including your height and weight, your general health or other health problems, and the type of cancer or condition you have. Your doctor will determine your exact dosage and schedule.